West Health Policy Center forms CIDSA to provide independent analysis of drug pricing policies

The West Health Policy Center, a nonprofit and nonpartisan policy research and education organization, announced today the formation of the Council for Informed Drug Spending Analysis (CIDSA), a group made up entirely of leading policy experts from the worlds of academia and healthcare.

CIDSA will serve as a resource for policymakers, news media and the public seeking objective information and analysis of policies aimed at lowering prescription drug prices and managing drug spending. Members of the group come from leading academic institutions including Harvard Medical School, Johns Hopkins, MIT Sloan School of Management, Boston University, Vanderbilt University School of Medicine and Washington University. CIDSA will provide standardized surveys on the effectiveness of policy proposals, fiscal estimates and analyses, and a dedicated space to publicize research and commentary on drug spending.

In an effort to provide clear and unbiased information about the range of implications drug pricing policies can have on consumers, industry, and the country writ large, we formed CIDSA. Our work will offer expert analyses of which policies will meaningfully or only minimally reduce drug spending, and in some cases expose proposals that will increases costs. Everything we do will be transparent and free of pharmaceutical industry influence."

Sean Dickson, Chair of CIDSA and Director of Health Policy, West Health Policy Center

The nine-member council includes:

  • Ge Bai, PhD, CPA, Associate Professor of Accounting at Johns Hopkins Carey Business School and Associate Professor of Health Policy & Management (joint) at Johns Hopkins Bloomberg School of Public Health.
  • Ernst R. Berndt, PhD, Professor of Applied Economics Emeritus at the MIT Sloan School of Management and Research Associate at the National Bureau of Economic Research.
  • Rena M. Conti, PhD, Associate Research Director of Biopharma & Public Policy for the Boston University Institute for Health System Innovation & Policy and Associate Professor at the Boston University Questrom School of Business.
  • Sean Dickson, JD MPH, Director of Health Policy at the West Health Policy Center. Dickson is a technical expert on the American drug system, including the full market lifecycle of pharmaceuticals.
  • Stacie Dusetzina, PhD, Associate Professor in the Department of Health Policy and an Ingram Associate Professor of cancer research at Vanderbilt University.
  • Richard G. Frank, PhD, is the Margaret T. Morris Professor of Health Economics in the Department of Health Care Policy at Harvard Medical School.
  • Rachel Sachs, JD MPH, is an associate professor of Law at Washington University in St. Louis. Her research explores the interaction of intellectual property law, food and drug regulation, and health law.
  • Ameet Sarpatwari, JD PhD, is an assistant professor of Medicine at Harvard Medical School, an associate epidemiologist at Brigham and Women's Hospital, and assistant director of the Program on Regulation, Therapeutics, And Law (PORTAL) within the Division of Pharmacoepidemiology and Pharmacoeconomics.
  • Mariana Socal, MD PhD MS MPP, is an assistant scientist in the Department of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study: Many cancer survivors worried about treatment disruptions during the pandemic